News

Stille AB (publ) today presents the report for the fourth quarter and full year 2024. Revenue amounted to MSEK 159.8 (77.3) driven by strong organic growth in surgical instruments, the successful acquisition of Fehling and solid growth in the US. Total growth amounted to 106.4 percent, of which 22.0 percent was organic growth.“Earnings growth remains solid with an adjusted EBITDA margin of 28.4...

Stille AB (publ) announces the Nomination Committee's proposal for a new board composition for the 2025 Annual General Meeting. Chairman of the Board Lars Kvarnhem has declined re-election, and Jón Sigurdsson is proposed as the new Chairman of the Board. The Nomination Committee proposes the re-election of Per Carlsson, Yonna Olsson, Victor Steien, and Jens Viebke, and that Jón Sigurdsson...

Torbjörn Sköld has informed the board of his intentions to leave his role as CEO in June 2025 to focus on new professional opportunities. Torbjörn Sköld has a notice period of six months and will continue in his current role during that time. The board has now begun the process of recruiting his successor. "Torbjörn has played a central role in further developing and strengthening...

Stille AB (publ) proudly unveils the imagiQ3™, the next generation of C-arm tables, designed to set new standards in visualization, operating room efficiency and patient safety. Stille is proud to announce the launch of imagiQ3™, the next generation of advanced C-arm tables. With a commitment to product leadership and innovation, the new table is designed for ultimate visualization and...

Stille AB (publ) today presents the report for the third quarter 2024. Revenue amounted to MSEK 127.9 (70.1) driven by strong organic growth in surgical instruments and the successful acquisition of Fehling. Total growth amounted to 82.4 percent, of which 7.4 percent was organic growth.“Organic growth remained robust, despite high comparable figures and slightly lower demand in the surgical table...

Stille AB (publ) today presents the report for the second quarter and first half of the year 2024. Revenue amounted to MSEK 142.6 (75.1) driven by strong organic growth in surgical instruments and the acquisition of Fehling. Total growth amounted to 89.9 percent, of which 7.4 percent was organic growth.“It is encouraging to see that organic growth remains robust, despite strong comparable figures.&rdquo...

The Annual General Meeting 2024 in Stille AB was held on Wednesday, May 8th at Eskilstunavägen 34 in Torshälla. The main resolutions passed at the Annual General Meeting were as follows. More detailed information about the contents of the resolutions may be obtained from the complete notice of the Annual General Meeting and the complete proposals, which are available on the company’s...

Stille AB (publ) today presents the report for the first quarter 2024. Revenue amounted to 139.7 MSEK (72.4) with Fehling consolidated from January 1st and strong underlying growth from both business units. Total growth amounted to 92.9 percent, and organic growth to 10.0 percent.“I am pleased to note that our growth remains strong in the first quarter and that the integration of Fehling goes...

Stille AB (publ) herby gives notice to attend the Annual General Meeting at Eskilstunavägen 34, 644 30, Torshälla, on May 8th, 2024, at 13.00. Right to participate To participate in the Annual General Meeting, one must be recorded as shareholder in the share register maintained by Euroclear Sweden AB on April 29th, 2024, and no later than May 2nd, 2024, at 12.00, to register their participation...

Today, Stille AB publishes the annual report for 2023. The report can be found on the company website www.stille.se. The annual report in its entirety is provided as an attachment to this press release. Torshälla, April 5th, 2024. Contact DetailsTorbjörn SköldCEO & President+46 (0)70 316 63 91 | torbjorn.skold@stille.se About UsStille AB (publ) develops, manufactures and markets...